Teva Pharmaceutical Industries (NYSE:TEVA) First Quarter 2025 Results

Key Financial Results

Revenue: US$3.89b (up 1.9% from 1Q 2024). Net income: US$214.0m (up from US$139.0m loss in 1Q 2024). Profit margin: 5.5% (up from net loss in 1Q 2024). EPS: US$0.19 (up from US$0.12 loss in 1Q 2024).

We check all companies for important risks. See what we found for Teva Pharmaceutical Industries in our free report.NYSE:TEVA Earnings and Revenue Growth May 8th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teva Pharmaceutical Industries EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) exceeded analyst estimates.

Looking ahead, revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 13% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Teva Pharmaceutical Industries' balance sheet.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments